ANN ARBOR, Mich., Aug. 09, 2016 -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that it has completed the buildout of its new Indiana production facility ahead of schedule. At this time the Company is installing the last piece of process equipment. Over the next week the Company will complete all pre-production checks and plans to start bringing in silkworms the week of August 15. This facility was initially established to fulfil the Company’s contract with the US Government. Additional production capacity from this facility will be used to satisfy material needs from industry collaborators and pending customers.
“The Indiana production center represents our first domestic production expansion and is a major step towards our near term goal of a fully self-contained US spider silk production facility,” said COO Jon Rice.
“The opening of this facility is an exciting moment for Kraig Labs and the future of commercially sustainable spider silk production,” said CEO and Founder Kim Thompson. “Our efforts in the lab have demonstrated the ability to recreate the incredible properties of spider silk, this facility now demonstrates that Kraig Labs can bring those materials to the market.”
To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.kraiglabs.com/newsletter.
For more information about Spider Silk, check it out at www.kraiglabs.com/spider-silk.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC (720) 288-8495 [email protected]


Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



